Following the consolidated results presented in the annual report of CSL, global Biotech company, 2021, answer the following questions:

(i) What is your assessment of the performance of the company over the years? 

(ii) What more external information do you need to draw a reasonable conclusion about the firm's performance, and why such information is necessary for an analysis?  

Consolidated Statement of Comprehensive Income For the Year Ended 30 June 2021 Continuing operations Sales and service revenue Influenza pandemic facility reservation fees Royalties and license revenue Other income Total operating revenue Cost of sales Gross profit Research and development expenses Selling and marketing expenses General and administration expenses Total expenses Operating profit Finance costs Finance income Profit before income tax expense Income tax expense Net profit for the year Other comprehensive income Items that may be reclassified subsequently to profit or loss Exchange differences on translation of foreign operations, net of hedges on foreign investments Items that will not be reclassified subsequently to profit or loss Actuarial gains/losses) on defined benefit plans, net of tax Total other comprehensive income/losses) Total comprehensive income for the year Earnings per share (based on net profit for the year) Basic earings per share Diluted earnings per share The consolidated statement of comprehensive income should be read in conjunction with the accompanying notes Notes 6 2 3 12 19 10 10 Consolidated Entity 2021 US$m 9,979.5 160.1 125.7 44.7 10,310.0 (4,466.7) 5,843.3 (1,001.4) (980.2) (731.7) (2,713.3) 3,130.0 (170.8) 3.9 2,963.1 (588.1) 2,375.0 198.9 83.4 282.3 2,657.3 US$ 5.22 5.21 2020 US$m 8,796.6 1454 158.5 50.3 9,150.8 (3,924.4) 5,226.4 (921.8) (896.2) (691.9) (2,509.9) 2,716.5 (150.8) 70 2,572.7 (470.2) 2,102.5 13.3 (13.6) (0.3) 2,102.2 US$ 4.63 4.61